z-logo
Premium
A comparison of four buprenorphine dosing regimens in the treatment of opioid dependence
Author(s) -
Petry Nancy M.,
Bickel Warren K.,
Badger Gary J.
Publication year - 1999
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1016/s0009-9236(99)70039-1
Subject(s) - dosing , buprenorphine , medicine , anesthesia , maintenance dose , placebo , opioid , maintenance therapy , crossover study , regimen , loading dose , pharmacology , chemotherapy , receptor , pathology , alternative medicine
Objectives This study compared 24‐, 48‐, 72‐, and 96‐hour buprenorphine dosing regimens in opioid‐dependent outpatients. Methods Fourteen subjects received buprenorphine in a double‐blind, placebo‐controlled crossover trial. Daily sublingual maintenance doses were 4 mg/70 kg (n = 5) and 8 mg/70 kg (n = 9). After a stabilization period of maintenance administration, subjects received, in a random order, four dosing regimens for five repetitions of each regimen: a maintenance dose every 24 hours, a doubled maintenance dose every 48 hours, a tripled maintenance dose every 72 hours, and a quadrupled maintenance dose every 96 hours. In the latter three dosing regimens, subjects received placebo on the interposed day(s). Study participation was contingent on opioid abstinence and daily clinic attendance. Measures of subjective opioid agonist and withdrawal effects were assessed daily. Results Relative to standard maintenance dosing, none of the higher doses induced agonist effects. Changes in indices of subjective withdrawal effects were noted as the time since the last active dose increased during intermittent dosing regimens, but the magnitude of these effects was relatively low and was comparable to those found in other alternate‐day dosing studies. Conclusions These results support the feasibility and safety of twice weekly buprenorphine dosing regimens. Clinical Pharmacology & Therapeutics (1999) 66 , 306–314; doi:

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here